886373-70-2

Usage

Uses

Used in Pharmaceutical Industry:
3-Pyridinamine, 5-chloro-2-methoxyis used as an intermediate in the synthesis of various pharmaceuticals for its potential therapeutic applications. Its unique structure allows for the development of new drugs with improved efficacy and selectivity in treating various diseases and conditions.
Used in Agrochemical Industry:
3-Pyridinamine, 5-chloro-2-methoxyis utilized as a building block in the synthesis of agrochemicals, such as pesticides and herbicides. Its properties contribute to the development of more effective and environmentally friendly products for agricultural use.
Used in Organic Synthesis:
3-Pyridinamine, 5-chloro-2-methoxyserves as a versatile building block in organic synthesis, enabling the creation of a wide range of chemical compounds with diverse applications. Its unique structure allows for further functionalization and modification, making it a valuable component in the synthesis of various organic compounds for research and industrial purposes.

Upstream product

• 22353-52-2 5-chloro-2-methoxy-3-nitropyridine 
• 21427-62-3 2,5-dichloro-3-nitropyridine 

Downstream Products

• 1261451-92-6 5-chloro-2-methoxypyridine-3-sulfonyl chloride 
• 1414805-55-2 [2-(1r,4r)-4-(2-[(5-chloro-2-methoxypyridin-3-yl)amino]-8-oxo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7,8-dihydro-9H-purin-9-yl)cyclohexyl]acetonitrile 
• 2183470-12-2 N-(3-((2-aminopyrimidin-5-yl)ethynyl)-2,4-difluorophenyl)-5-chloro-2-methoxypyridine-3-sulfonamide 
• 1309778-84-4 4-chloro-N-[5-chloro-2-(methyloxy)-3-pyridinyl]-3-(trifluoromethyl)benzene-sulfonamide 

Relevant academic research and scientific papers

Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases

Janus kinases (JAKs) have a key role in regulating the expression and function of relevant inflammatory cytokines involved in asthma and chronic obstructive pulmonary disease. Herein are described the design, synthesis, and pharmacological evaluation of a series of novel purinone JAK inhibitors with profiles suitable for inhaled administration. Replacement of the imidazopyridine hinge binding motif present in the initial compounds of this series with a pyridone ring resulted in the mitigation of cell cytotoxicity. Further systematic structure-activity relationship (SAR) efforts driven by structural biology studies led to the discovery of pyridone 34, a potent pan-JAK inhibitor with good selectivity, long lung retention time, low oral bioavailability, and proven efficacy in the lipopolysaccharide-induced rat model of airway inflammation by the inhaled route.

SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS

Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also disc

PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS

New pyridin-2(1H)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

Pyridin-2(1h)-one derivatives as jak inhibitors

New pyridin-2(1H)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS

New imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES

Compoundshaving the chemical structure of formula (I) are disclosed; as well as process for theirpreparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).